Novasep, a supplier of services and technologies for the life sciences industry, has signed a manufacturing services agreement with Exelixis, an oncology-focused biotech, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC) for oncology applications.   XB002 is a novel ADC composed of a human monoclonal antibody against tissue factor that is conjugated to a cytotoxic agent and leverages proprietary linker-payload technology. After bin...